Maira P Campos, M.D., MPH
Investigator
Maira P Campos, MD, MPH is a board-certified hematologist-oncologist with specialized training in internal medicine, cancer care, and clinical research. She earned her Doctor of Medicine and Master of Public Health degrees from the ABC Foundation School of Medicine in São Paulo, Brazil. Dr. Campos completed her internal medicine residency at Jackson Memorial Hospital/University of Miami, followed by a hematology and oncology fellowship at the David Geffen School of Medicine at UCLA.
Dr. Campos currently serves as a hematologist-oncologist at Ridley-Tree Cancer Center in Santa Barbara, California. Prior to this role, she practiced at St. Charles Cancer Center in Oregon, where she was a breast cancer research site lead, and held an academic appointment as a clinical instructor at UCLA.
Her clinical and research interests include breast cancer, gynecologic malignancies, and cancer-related fatigue. She has authored multiple peer-reviewed publications and presented her work at national and international conferences, including the American Society of Clinical Oncology (ASCO).
Dr. Campos is committed to advancing cancer care through research, education, and compassionate, patient-centered treatment. She is fluent in English, Portuguese, and Spanish, allowing her to provide culturally competent care to diverse patient populations.
Clinical trials
- Clinical trial
Adjuvant Triple NegativeBreast Cancer Ascent-05
A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
Status: Open to Enrollment
- Clinical trial
Advanced or Metastatic Breast Cancer C4551002
An Interventional, Open-Label, Randomized, Multicenter, Phase 3 Study of PF-07248144 Plus Fulvestrant Compared to Investigator's Choice of Therapy in Adult Participants With Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Cancer Whose Disease Progressed After Prior CDK4/6 Inhibitor-based Therapy
Status: Open to Enrollment
- Clinical trial
Advanced Ovarian Cancer Catalina-2
Catalina-2: A Phase 2 Study Evaluating the Efficacy and Safety of TORL-1-23 in Women With Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6 (TORL123-002)
Status: Open to Enrollment
A Phase III, Open-label, Multi-center, Randomized Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive Metastatic Castration Resistant Prostate Cancer
Status: Open to Enrollment
- Clinical trial
Metastatic HER2-positive Breast Cancer JZP598-303
A Phase 3, Randomized, Open-label, Multicenter, Controlled Study to Evaluate the Efficacy and Safety of Zanidatamab in Combination With Physician's Choice Chemotherapy Compared to Trastuzumab in Combination With Physician's Choice Chemotherapy for the Treatment of Participants With Metastatic HER2-positive Breast Cancer Who Have Progressed on, or Are Intolerant to, Previous Trastuzumab Deruxtecan Treatment
Status: Open to Enrollment